Use of a blood-flow decrease preventing agent in conjunction with insufflating gas

Abstract

A blood-flow decrease preventing agent is used to negate or reduce the decreased oxygen delivery in abdominal organs caused by insufflating gas. Preferably a gas is delivered into the abdominal cavity consisting essentially of the insufflating gas and the blood-flow decrease preventing agent. Very preferably, a gas is used consisting essentially of carbon dioxide as the insufflating gas and ethyl nitrite as the blood-flow to abdominal organ decrease preventing agent.

1 . A method for negating or reducing decrease in blood flow in an abdominal organ which would otherwise have decreased oxygen delivery because of decreased blood-flow therein because of being contacted with insufflating gas, comprising contacting said abdominal organ with a blood-flow to abdominal organ decrease preventing agent in a therapeutically effective amount. 
     
     
         2 . The method of  claim 1  where the step of contacting said abdominal organ with a blood-flow to abdominal organ decrease preventing agent in a therapeutically effective amount comprises delivering the blood-flow to abdominal organ decrease preventing agent to the abdominal cavity as part of a gas consisting essentially the blood-flow to abdominal organ decrease preventing agent in therapeutically effective amount and an insufflating gas. 
     
     
         3 . The method of  claim 2  where the insufflating gas is carbon dioxide. 
     
     
         4 . The method of  claim 3  where the blood-flow to abdominal organ decrease preventing agent is ethyl nitrite. 
     
     
         5 . The method of  claim 4  where the gas contains from 1 to 1,000 ppm ethyl nitrite. 
     
     
         6 . The method of  claim 5  where the gas contains from 50 to 200 ppm ethyl nitrite. 
     
     
         7 . The method of  claim 1  where the amount of blood-flow to abdominal organ decrease preventing agent is effective to relieve hypoxemia. 
     
     
         8 . The method of  claim 1  where the blood-flow to abdominal organ decrease preventing agent is administered as a nebulized dry powder or as a solution. 
     
     
         9 . A gas consisting essentially of insufflating gas and a blood-flow to abdominal organ decrease preventing agent in a therapeutically effective amount. 
     
     
         10 . The gas of  claim 9  where the insufflating gas is carbon dioxide and the blood-flow to abdominal organ decrease preventing agent is ethyl nitrite. 
     
     
         11 . The gas of  claim 10  containing 1 to 1,000 ppm ethyl nitrite. 
     
     
         12 . The gas of  claim 11  containing 50 200 ppm ethyl nitrite.